NASDAQ:IMNM Immunome Q1 2025 Earnings Results & Report $17.58 -1.57 (-8.20%) Closing price 04:00 PM EasternExtended Trading$17.60 +0.02 (+0.11%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immunome beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 12, 2025. The company reported EPS of -$0.52 versus the -$0.66 consensus estimate, while revenue of $2.93 million topped the $0.46 million estimate by $2.47 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 12, 2025TimeBefore Market OpensConference Call12:00 AM ET Immunome EPS ResultsActual EPS-$0.52Consensus EPS -$0.66Beat/MissBeat by +$0.14One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersImmunome Revenue ResultsActual Revenue$2.93 millionExpected Revenue$0.46 millionBeat/MissBeat by +$2.47 millionYoY Revenue GrowthN/AUpcoming EarningsImmunome's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immunome Q1 2025 Earnings FAQ Did Immunome beat earnings estimates for Q1 2025? Immunome (NASDAQ:IMNM) reported earnings of -$0.52 per share for Q1 2025, beating the consensus estimate of -$0.66. The report was announced on Monday, May 12, 2025. What was Immunome's revenue for Q1 2025? Immunome reported revenue of $2.93 million for Q1 2025, against a consensus estimate of $0.46 million. When is Immunome's next earnings date? Immunome's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immunome on the company's earnings history page. Immunome Earnings HeadlinesCritical Analysis: Arbutus Biopharma (NASDAQ:ABUS) and Immunome (NASDAQ:IMNM)October 10 at 4:29 AM | americanbankingnews.comImmunome (IMNM) Gets a Hold from Stifel NicolausOctober 7, 2026 | theglobeandmail.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Immunome, Inc. (NASDAQ:IMNM) Stock Has Average Target Price of $34.25October 7, 2026 | americanbankingnews.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 6, 2026 | businesswire.comImmunome Restructures BMS Deal, Gains Key Patent RightsOctober 5, 2026 | tipranks.comSee More Immunome Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email. Email Address About ImmunomeImmunome (NASDAQ:IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer and immune-related diseases. The company uses its antibody discovery and development capabilities to identify potentially differentiated treatments designed to address significant unmet medical needs. Immunome’s research activities are centered on building a pipeline of monoclonal antibody programs, including candidates directed at targets relevant to oncology and inflammatory or immune-mediated conditions. Its work encompasses target discovery, antibody engineering, preclinical development and clinical-stage drug development. The company was founded in 2008 and is headquartered in Exton, Pennsylvania. Immunome initially developed its technology around the discovery of antibodies from human immune cells and applied that expertise to infectious-disease research, including programs related to COVID-19. Clay B. Siegall, Ph.D., serves as president and chief executive officer.View Immunome ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
